TNew evidence has been found that links the spread of human papillomavirus (HPV) through oral sex with some throat cancers in both men and
The study, published in the New England Journal of Medicine, found that having multiple oral sex partners tops the list of sex practices that boosts the risk of HPV-linked cancer, regardless of tobacco or alcohol
However, people should be reassured that oropharyngeal cancer is relatively uncommon, and the overwhelming majority of people with an oral HPV infection probably will not get throat cancer.
The original study
Oropharyngeal carcinoma related to human papillomavirus.
Incidence is increasing rapidly, with implications for prognosis and policy
Hisham Mehanna, director 1, Terence M Jones, eader2, Vincent Gregoire, professor3, K Kian Ang, professor4
1.Institute of Head and Neck Studies and Education (InHANSE), University Hospital, Coventry CV2 2DX
2.Liverpool CR-UK Cancer Centre, School of Cancer Studies, Division of Surgery and Oncology, University of Liverpool, Liverpool L69 3GA
3.Radiation Oncology Department and Centre for Molecular Imaging and Experimental Radiotherapy, Université Catholique de Louvain, 1200 Brussels, Belgium
4.Department of Radiation Oncology, University of Texas, MD Anderson Cancer Centre, Houston, TX 77030, USA
Head and neck cancer is the sixth most common cancer, with about 640,000 new cases each year worldwide. Despite an overall marginal decline in the incidence of most head and neck cancers in recent years,1 the incidence of oropharyngeal squamous cell carcinoma has increased greatly, especially in the developed world. In the United States, the incidence of oropharyngeal squamous cell carcinoma increased by 22% from 1.53 per 100,000 to 1.87 per 100,000 between 1999 and 2006, after showing no change between 1975 and
1999.(1) The United Kingdom has seen a 51% increase in oral and oropharyngeal squamous cell carcinoma in men from seven per 100,000 to 11 per 100,000 between 1989 and
The increase in incidence of oropharyngeal squamous cell carcinoma seems to be accounted for by a rise in human papillomavirus (HPV) related oropharyngeal carcinoma. A recent retrospective study showed a progressive proportional increase in the detection of HPV in biopsies taken to diagnose oropharyngeal squamous cell carcinoma in the Swedish county of Stockholm over the past three decades (23.3% in 1970s, 29% in 1980s, 57% in 1990s, 68% between 2000 and 2002, 77% between 2003 and 2005, and 93% between 2006 and
2007).(3) Similarly, HPV related oropharyngeal carcinoma has been reported in 60-80% of recent oropharyngeal biopsy samples in studies conducted in the US, compared with 40% in the previous
decade.(4) More research is needed to establish the incidence of HPV related oropharyngeal carcinoma in African, Asian, and South American
HPV related oropharyngeal carcinoma seems to be a new and distinct disease
entity.(5) It has a more favourable prognosis than non-HPV related oropharyngeal carcinoma, particularly in non-smokers. Two recent randomised trials have shown significantly improved two year overall survival in stage III and stage IV HPV type 16 related oropharyngeal carcinoma compared with non-HPV related cancers (87.5% and 95% compared with 67.2% and
62%).(5)(6) The reason for this improved survival is not fully understood; it may be the result of an increased immunological response to HPV antigens in the
host,(7) or an increased sensitivity to radiotherapy because the presence of wild-type p53 causes an increase in
apoptosis.(8) Smoking seems to worsen outcomes for patients with HPV related oropharyngeal carcinoma—outcomes are similar to non-smokers with non-HPV related oropharyngeal
Sexual transmission of HPV—primarily through orogenital intercourse might be the reason for the increase in incidence of HPV related oropharyngeal carcinoma. A pooled analysis of eight multinational observational studies that compared 5642 cases of head and neck cancer with 6069 controls found that the risk of developing oropharyngeal carcinoma was associated with a history of six or more lifetime sexual partners (odds ratio 1.25, 95% confidence interval 1.01 to 1.54), four or more lifetime oral sex partners (3.36, 1.32 to 8.53), and—for men—an earlier age at first sexual intercourse (2.36, 1.37 to
The rising incidence of HPV related oropharyngeal carcinoma has implications for health service providers and commissioners. Patients are typically younger and employed, and—because outcomes seem to be more favourable than for patients with non-HPV related carcinoma—they will live longer with the functional and psychological sequelae of their treatment. Consequently, they need prolonged support from health, social, and other services, and may require help in returning to work.
There are also public health implications. Female only HPV vaccination programmes may affect the incidence of HPV related oropharyngeal carcinoma. A recent modelling study of the effects of HPV vaccination in males concluded that routinely vaccinating boys for HPV could not be justified on health economic
grounds.(11) However, the low incidence of HPV related oropharyngeal carcinoma in that study has led to concern because the recent rapid rise in HPV related oropharyngeal carcinoma may alter the cost effectiveness of vaccinating boys before they become sexually
Studies reporting treatment outcomes for head and neck cancer, particularly oropharyngeal carcinoma, must now account for HPV status, because of its association with improved prognosis. Newly diagnosed patients may wish to know their HPV status, and future stratification by HPV status will probably be necessary. Widely used methods to detect tumour associated HPV infection include detection of HPV-16 DNA using polymerase chain reaction or in situ hybridisation, detection of HPV E6 or E7 mRNA using reverse transcriptase-polymerase chain reaction, and immunohistochemical analysis of p16 overexpression, all of which act as markers of transcription or “activity.” However, standardised definitions and cut-off points must be agreed to identify the best test or combination of tests for clinical diagnosis, and to regulate quality assurance in clinical
To date, we have no good evidence to support managing patients with HPV related head and neck cancer differently from those whose tumours are not HPV related, although several studies are being planned to evaluate different treatment options. Until data from such studies are available, we suggest that clinicians should not change their current treatment policies for patients with HPV related oropharyngeal squamous cell carcinoma, but should aim to offer all patients with oropharyngeal cancer the opportunity to enrol in an appropriate clinical trial.
Cite this as: BMJ 2010;340:c1439
Competing interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that: (1) None have support from any companies for the submitted work; (2) HM is the director of an institute that does contract work for GlaxoSmithKline that has interests in head and neck cancers; (3) Their spouses, partners, and children have no financial relationships that may be relevant to the submitted work; and (4) TMJ holds a CR-UK research grant for a phase I clinical trial involving patients with HPV related oropharyngeal carcinoma and for which Advaxis will be providing a therapeutic vaccine (ADXS11-001) free of
Provenance and peer review: commissioned not externally peer reviewed
1. National Cancer Institute. Surveillance epidemiology and end results. [?date]
2. Cancer Research UK. Oral cancer—UK incidence
3. Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer2009;125:362-6.
4. Worden FP, Hooton J, Lee J, Eisbruch A, Wolf GT, Prince M, et al. Association of tobacco (T) use with risk of distant metastases (DM), tumor recurrence, and death in patients (pts) with HPV-positive (+) squamous cell cancer of the oropharynx (SCCOP). J Clin Oncol 2009;27:15s.
5. Worden FP, Kumar B, Lee JS, Wolf GT, Cordell KG, Taylor JM, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol2008;26:3138-46.
6. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst2008;100:261-9.
7. Dahlstrand H, Dahlgren L, Lindquist D, Munck-Wikland E, Dalianis T. Presence of human papillomavirus in tonsillar cancer is a favourable prognostic factor for clinical outcome. Anticancer Res2004;24:1829-35.
8. Lindel K, Beer KT, Laissue J, Greiner RH, Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx. A radiosensitive subgroup of head and neck carcinoma. Cancer 2001;92:805-13.
9. Gillison ML, Harris J, Westra W, Chung C, Jordan R, Rosenthal D, et al. Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. ASCO Meeting Abstracts. J Clin Oncol2009;27(15S):6003.
10. Heck JE, Berthiller J, Vaccarella S, Winn DM, Smith EM, et al. Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol 2009; Published online 18
11. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ2009;339:b3884.
12. Sturgis EM, Dahlstrom KR. Inaccurate assumptions about oropharyngeal cancer. BMJ 2009;339:b4525.